{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.95","value":"0.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death after 4 year in the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A\n\ndoxorubicin hydrochloride: Given IV\n\nliposomal vincristine sulfate: Given IV\n\nconventional surgery\n\n3-dimensional conformal radiation therapy\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\netoposide: Given IV","id":"OG000","title":"Stage IV and Slow Incomplete Response (SIR) of Lung Metastases"}],"paramType":"NUMBER","populationDescription":"Analysis includes only eligible patients.","reportingStatus":"POSTED","timeFrame":"At 4 years","title":"Event Free Survival (EFS) Probability","type":"PRIMARY","unitOfMeasure":"Probability of EFS at 4 years"}